Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Alcohol-related Liver Disease: early-phase trial registry
3 of 4 indexed Alcohol-related Liver Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Alcohol-related Liver Disease: 4 US clinical trials tracked, 3 recruiting.
Alcohol-related Liver Disease is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is HepQuant, running 1 of these trials.
Enrollment posture brief
Registry condition alcohol-related-liver-disease
OPEN 3 | RECR 75% | LATE 0 | EARLY 1 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Alcohol-related Liver Disease lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Alcohol-related Liver Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Alcohol-related Liver Disease is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
University of Wisconsin, Madison
NCT06305624
Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
Henry Ford Health System
NCT06269510
Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease
HepQuant
NCT07060547
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
Novo Nordisk A/S
NCT06409130
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Alcohol-related Liver Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Alcohol-related Liver Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Alcohol-related Liver Disease page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Alcohol-related Liver Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- HepQuant sponsors the most Alcohol-related Liver Disease trials on record, review their full trial history before evaluating a specific study. See HepQuant's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Alcohol-related Liver Disease condition card totals 4 registered trials; most-linked intervention Cagrilintide + semaglutide; top US site state Michigan. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.